Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more
Meta Biomed Co. Ltd (059210) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.009x
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has a cash flow conversion efficiency ratio of 0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.05 Billion) by net assets (₩121.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Meta Biomed Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Meta Biomed Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meta Biomed Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etoiles Capital Group Co., Ltd. Class A Ordinary Shares
NASDAQ:EFTY
|
N/A |
|
Ellaktor S.A
AT:ELLAKTOR
|
-0.004x |
|
Reach Subsea
OL:REACH
|
0.264x |
|
Reach Subsea ASA
LSE:0EMB
|
N/A |
|
Cross Timbers Royalty Trust
NYSE:CRT
|
1.312x |
|
Lanvin Group Holdings Limited
NYSE:LANV
|
0.322x |
|
A W FOOD SERVICES OF CANADA INC
TO:AW
|
0.104x |
|
MARX Biotech Co., Ltd.
TWO:7731
|
-0.410x |
Annual Cash Flow Conversion Efficiency for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Meta Biomed Co. Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.34 Billion | ₩22.63 Billion | 0.242x | +72.44% |
| 2023-12-31 | ₩72.66 Billion | ₩10.22 Billion | 0.141x | -6.98% |
| 2022-12-31 | ₩60.59 Billion | ₩9.16 Billion | 0.151x | -20.83% |
| 2021-12-31 | ₩58.32 Billion | ₩11.14 Billion | 0.191x | +88.43% |
| 2020-12-31 | ₩47.98 Billion | ₩4.86 Billion | 0.101x | +88.40% |
| 2019-12-31 | ₩53.27 Billion | ₩2.86 Billion | 0.054x | +150.87% |
| 2018-12-31 | ₩49.97 Billion | ₩-5.28 Billion | -0.106x | -1857.36% |
| 2017-12-31 | ₩46.01 Billion | ₩-248.51 Million | -0.005x | -105.54% |
| 2016-12-31 | ₩51.59 Billion | ₩5.03 Billion | 0.098x | +0.59% |
| 2015-12-31 | ₩50.87 Billion | ₩4.93 Billion | 0.097x | +1547.11% |
| 2014-12-31 | ₩44.20 Billion | ₩-296.24 Million | -0.007x | -108.04% |
| 2013-12-31 | ₩44.54 Billion | ₩3.71 Billion | 0.083x | -11.04% |
| 2012-12-31 | ₩40.89 Billion | ₩3.83 Billion | 0.094x | -10.84% |
| 2011-12-31 | ₩39.05 Billion | ₩4.10 Billion | 0.105x | -- |